Mo Jiang, Ph.D.
Mo Jiang, Ph.D., is a Co-Investigator with Medicines for All and an Assistant Professor in the Department of Chemical and Life Science Engineering at VCU. With M4ALL, Jiang focuses on process intensification for advanced pharmaceutical manufacturing, such as designing novel processes and platforms of continuous crystallization and/or evaporation. Jiang holds a B.S. in biology from Tsinghua University, an M.S. in chemical engineering from the University of Illinois at Urbana-Champaign, and a Ph.D. in chemical engineering from the Massachusetts Institute of Technology.
Tom Roper, Ph.D.
Thomas D. Roper, Ph.D., joined VCU in 2016 after a 22-year career at GlaxoSmithKline Pharmaceuticals. He held senior positions in the Pharmaceutical Development Division of GSK, including responsibilities for process R&D and analytical development for active pharmaceutical ingredients for the US, and most recently was the global head of exploratory development sciences for GSK. Roper specializes in efforts to bring engineering and science closer to patients via novel medicinal technologies. He holds a B.S. in chemistry from VCU and a Ph.D. in organic chemistry from the University of Virginia. He was a postdoctoral associate in organic chemistry at Harvard University
Joshua Sieber, Ph.D.
Joshua Sieber, Ph.D., is a Co-Investigator with Medicines for All and an Assistant Professor in the Department of Chemistry at VCU. He joined VCU in 2018 after a 7-year stint in industry in the process chemistry group at Boehringer Ingelheim Pharmaceuticals, Inc. where he gained expertise in developing synthetic processes for the large-scale synthesis of new APIs and the application of catalysis to large-scale processes. He obtained a Ph.D. from Boston College in 2008 followed by an American Cancer Society postdoctoral fellow at Stanford University where he gained experience in catalysis development and the total synthesis of natural products. His research interests focus on applying his background in catalysis, total synthesis, and process chemistry to develop new catalysts and catalytic reactions that target industrial-scale applications.
Bruce V. Thomas J.D.
Bruce Thomas is a recognized expert in the areas of medication adherence and access, with experience leading efforts to address these issues at scale to improve patients’ lives. As a consultant and grantee to the Bill & Melinda Gates Foundation since 2014, he leads the development, testing and scale-up of new approaches to improve differentiated care for TB and HIV patients in China, India, and Sub-Saharan Africa. In his work with VCU’s Medicines For All Institute, he works to ensure that the global health community capitalizes fully on the Institute’s innovative approaches to improve access to lifesaving treatments. He previously served as president of MeadWestvaco Healthcare, establishing a proprietary manufacturing system and supply chain in India to bring generic pharmaceutical products to North America in ready-to-dispense, adherence-enhancing packaging for Walmart’s breakthrough $4 generic program.
Anton Toutov, Ph.D.
Anton is the Founder and Chief Science Officer at Fuzionaire and Fuzionaire Diagnostics — VC-funded chem-tech start-ups with operations in the US, Canada, and Japan. He is also an Assistant Professor of Chemistry (by courtesy) in the Department of Chemical and Life Sciences Engineering at Virginia Commonwealth University (VCU).
A scientist-entrepreneur, Anton’s PhD thesis in chemistry was awarded Caltech’s Demetriades Thesis Prize in 2016, was the subject of the Resnick Institute short documentary Element 19, and has been spotlighted by Nature magazine, NASA, Scientific American, The UK Royal Society, the NSF, and other publications. He has written for Wired, TNW, The Conversation, and other mainstream outlets on a variety of topics including drug discovery, quantum computing, and emissions control.
Anton has authored 10 scholarly publications in the chemical sciences and is an inventor on over 60 patent grants and applications. He has a BSc in chemistry from Queen’s University and a PhD in organic chemistry from the California Institute of Technology, working under Nobel Laureate Bob Grubbs, where he held NSERC, Dow-Resnick and Bristol—Myers Squibb fellowships.